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Abstract: Glucagon-like peptide 1 receptor agonists (GLP1-RA) are prominent agents in
the therapeutics of type 2 diabetes mellitus due to their exemplary efﬁcacy in both pre-
prandial and postprandial glycemia, their safety, low risk of hypoglycemia, their multilevel
pathophysiological superiority, weight loss and importantly the observed beneﬁts in cardio-
vascular disease reduction. Their major drawback is the subcutaneous route of administra-
tion, constituting a barrier to adoption and reason for treatment discontinuation. Thus, the
development of an oral GLP1-RA agent would promote medication adherence and quality of
life, further consolidating its beneﬁcial effects in real-life clinical practice. However, this task
is hampered by suboptimal gastrointestinal protein absorption. Yet, the introduction of oral
semaglutide, a modiﬁed form of semaglutide with the addition of a carrier sodium N-(8-[2-
hydroxybenzoyl] amino) caprylate, may have provided a safe and effective way to reach
systemic circulation while other molecules are in development. Whether this molecule still
has the impressive cardiovascular effects demonstrated with the use of its precursor remains
to be explored. However, to date, its efﬁcacy and safety have already been showcased in a
randomized trial. More research is warranted in order to further consolidate these ﬁndings
across different type 2 diabetes mellitus (T2DM) subpopulations, and adequately powered
studies with a longer follow-up that would allow the exploration of microvascular and
macrovascular complications are needed. Finally, studies comparing oral semaglutide and
similar molecules with other currently established antidiabetic agents to evaluate the relative
efﬁcacy, the cost-effectiveness and further understand its place in T2DM therapeutic algo-
rithm are needed. This review focuses on the development of oral GLP1-RA agents and
summarizes the challenges, milestones and expected beneﬁts associated with a successful
introduction.
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Introduction
Glucagon-like peptide 1 receptor agonists (GLP1-RA) constitute a class of antidia-
betic medications with unique a set of characteristics.1 Despite within class variations
in terms of clinical efﬁcacy due to different biochemical structures and pharmacoki-
netics proﬁles, all members of GLP1-RA class (liraglutide, albiglutide, dulaglutide,
lixisenatide and semaglutide) have shown signﬁcant hypoglycaemic efﬁcacy.
Second, their safety proﬁle is overall satisfactory considering the low risk of serious
adverse events. Moreover, their supplementary effects on satiety and weight loss are
essential in the management of type 2 diabetes mellitus (T2DM) to the extent that
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liraglutide has already been repurposed as an anti-obesity
medication, and the 3 mg dose is already approved and used
in clinical practice. Last but not least, their favorable cardi-
ovascular (CV) properties in blood pressure, endothelial
function and myocardial metabolism2,3 exempliﬁed in the
LEADER trial4 and other studies,5 in which a signiﬁcantly
lower risk of CVD events was demonstrated with liraglutide
in patients with T2DM, are of major clinical importance
when considering the increased risk of CV and all-cause
mortality in patients with T2DM.6
On top of the above hard clinical outcomes, the use of
GLP1-RA is associated with unique beneﬁcial effects from
the pathophysiological perspective as well. This class has
a glucose-dependent nature of action and is admittedly one
of the most efﬁcacious amongst glucose-lowering agents
in addressing GLP-1 resistance and hyperglucagonemia,
thus combating in multiple ways the multifactorial com-
ponents of T2DM.1
Considering the above, it comes as no surprise that sev-
eral formulations of GLP1-RA have been tested and devel-
oped and several members of the family have been
introduced in everyday practice with different pharmacoki-
netic properties. In 2005, US Food and Drug Administration
(FDA) approved exenatide for the treatment of type 2 DM.7
Long-acting liraglutide was approved in 2009 and 2010 by
the European Medicines Agency and FDA, respectively,
followed by lixisenatide (2013 EMA, 2016 FDA), albiglutide
(2014 for both EMA and FDA) and dulaglutide (2014 for
both EMA and FDA)8 On December 5, 2017, semaglutide
was approved in the USA for its use as subcutaneous injec-
tion, while in Europe, semaglutide was approved by the
EMA on February 8, 2018.9,10
However, notwithstanding the above admittedly well-
grounded beneﬁts associated with the use of GLP1-RA,
both the adoption and adherence to treatments may be
considered as low11 in the real world. One of the major
reasons is the high dropout rate,11 possibly due to the
nausea-related side effects and importantly the fact that
these formulations are till date injectable. The recent
introduction of weekly instead of daily injection
schemes is an advance, but still, the injectable therapy
places a signiﬁcant psychological and practical burden
to patients, who may prioritize ease of use associated
with an oral formulation over superior pathophysiologi-
cal properties. On top of this, oral formulations do not
require speciﬁc conditions of sterility and other precau-
tions against possible particle contamination, which may
also have cost implications.12
The above issues should be addressed by the develop-
ment and introduction of oral GLP1-RA formulations,
which are preferable by patients and related to better
compliance and convenience.13,14 This is why the recent
advances with semaglutide, the ﬁrst and more advanced
form of oral GLP1-RA, are considered a major step for-
ward in the therapeutics of diabetes.1 These steps will be
summarized in this review.
Methods
A systematic search using Medline and the Cochrane Library
from inception to 29 September 2018 was performed to
identify studies that semaglutide was used as a treatment
for T2DM. We used keywords and search terms that had
been identiﬁed from initial scoping searches, target refer-
ences and browsing of database thesauruses (data supple-
mentary 1). A basic search strategy was developed for
PubMed and modiﬁed accordingly for other research
engines. We also searched clinicaltrials.gov. References of
relevant studies were perused. The study selection procedure
is provided in Figure 1. A complementary literature search
focusing on other similar agents was also undertaken.
Results and discussion
Synopsis of the precursor molecule
(subcutaneous semaglutide)
The injectable formulation of semaglutide has an increased
afﬁnity for native human GLP1. Semaglutide molecule
resembles native GLP1 sharing a 94% structural homology
and is modiﬁed at 3 positions; position 8, where alanine is
substituted by alpha-aminoisobutyric acid and thus increas-
ing resistance to DPP-4 degradation, position 34, where
lysine is changed by arginine and thus, preventing wrong
binding of C-18 fatty acid, and position 26, where lysine is a
acylated with a glutamate spacer15 to provide speciﬁc bind-
ing to albumin. The semaglutide molecule differs from its
precursor molecule liraglutide in two positions; alanine at the
second position is replaced by α-aminoisobutyric acid and
lysine 26 residue is acylated with a stearic diacid instead of
palmitate. These changes result in extending semaglutide
half-life to approximately 1 week, thus permitting a weekly
delivery dosage scheme.16–18 The strong afﬁnity for albumin
also contributes to the long duration of action.17,19 The spacer
region (glutamic acid moiety) between the C-18 fatty di-acid
sidechain and the peptide is considered to be important for
potency, whereas the fatty acid is considered to be important
for both potency and protraction.20
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The metabolism of semaglutide takes place in two
steps: the ﬁrst step is the proteolytic cleavage of the
peptide backbone and the second one is β-oxidation
(involving dehydrogenation, hydratation, dehydrogena-
tion, thiolytic cleavage) of the fatty di-acid chain, pro-
cedures that are not conﬁned to speciﬁc organs.15
Following β-oxidation, semaglutide degradation pro-
ducts are excreted mainly via urine and to lesser extent
via the feces, involving hepatic metabolism in part.
Amongst semaglutide metabolites, the most dominant
metabolite is traceable up to 7.7% of all semaglutide
material and found to consist of several co-eluting
components.15
Moreover, the pharmacokinetics of semaglutide are not
signiﬁcantly affected by renal or hepatic impairment,21,22
and thus, no dose adjustment is required in these popula-
tions. Of note, the kidney function appears to be unaf-
fected by the use of semaglutide.23 The level of creatine
clearance also does not appear to affect the pharmacoki-
netics of semaglutide,22 yet clinical experience in patients
with end-stage renal disease is limited and thus not recom-
mended. No signiﬁcant drug interactions were detected
Records identified through 
database searching
(n =156)
Duplicates removed
(n=11)
Records screened based on title 
and abstract
(n=145)
Records excluded
(n=129)
-Sub-analysis (n=4)
-Protocols (n=34)
-Not primary studies (n=80)
-Non-relevant (n=10)
-Cost analysis (n=1)
Full-text articles assessed for 
eligibility
(n=16)
Records excluded
(n=2)
- Non-relevant (n=2)
Full-text screening
(n=18)
Records identified from reference lists 
(n=4)
Figure 1 Summary of evidence search and selection.
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when semaglutide was coadministered with metformin,
warfarin, digoxin, atorvastatin, ethinyl estradiol and levo-
norgestrel in healthy adults.18,24
The efﬁcacy and safety of injectable semaglutide was
explored in the SUSTAIN trials program. Overall, sema-
glutide was associated with improved glycaemic control,
when used either as monotherapy or as add-on therapy in
patients with T2DM against both placebo and active com-
parators (including other GLP-1 RAs). The results of the
published SUSTAIN trials are summarized in Table 1.
Compared with placebo, a signiﬁcant decrease in HbA1c
with both dosages (1.45% and 1.55% for 0.5 mg and 1.0
mg, respectively) was observed in SUSTAIN 1. Moreover,
body weight reduced signiﬁcantly by 3.73 kg and 4.53 kg
with 0.5 mg and 1.0 mg, respectively.25 The magnitude of
this effect is considered exceptionally high.
Adult patients with T2DM treated by metformin, thia-
zolidinediones/rosiglitazone or both without adequate gly-
caemic control after 3 months were enrolled in SUSTAIN 2
trial to explore the comparative effectiveness of semaglutide
against sitagliptin. The primary outcome was the mean
HbA1c change from baseline to 56 weeks, which was sig-
niﬁcantly reduced in both semaglutide groups against sita-
gliptin. Notably, body weight reduced up to ~6.0% for the
highest dosage of semaglutide.26
SUSTAIN 3 trial compared semaglutide 1.0 mg with
exenatide extended release 2 mg in adults with T2DM
not controlled on one or two oral antidiabetic agents.
After 56 weeks, Hb1Ac and the body weight were sig-
niﬁcantly decreased in the semaglutide group.27 The
results were similar when semaglutide was compared
to insulin glargine and dulaglutide, but importantly,
fewer hypoglycaemic episodes were recorded with
semaglutide.28–30
In addition to its glucose- and weight-lowering efﬁ-
cacy, semaglutide, when used as add-on standard care in
patients with T2DM and high cardiovascular disease, was
found to be associated with signiﬁcantly lower risk of
cardiovascular death, nonfatal myocardial infarction,
stroke and new or worsening nephropathy compared to
placebo.31 This ﬁnding is regarded as of paramount impor-
tance in the long-term clinical care of patients with T2DM.
Table 1 Effectiveness of semaglutide versus control in HbA1c and weight reduction
Study Duration (weeks) Route Dose (mg) Comparator HbA1c (%)
Reduction
Weight (kg) Reduction
SUSTAIN 125 30 subcutaneous 0.5
1.0
Placebo −1.43*
−1.53*
−2.75*
−3.56*
SUSTAIN 227 56 subcutaneous 0.5
1.0
Sitagliptin 100 mg −0.77*
−1.06*
−2.35*
−4.2*
SUSTAIN 328 56 subcutaneous 1.0 Exanatide ER −0.62* −3.78*
SUSTAIN 429 30 subcutaneous 0.5
1.0
(+insulin)
Glargine U100 −0.38*
−0.81*
−4.62*
−6.33*
SUSTAIN 531 30 subcutaneous 0.5
1.0
(+insulin)
Placebo −1.35*
−1.75*
−2.31*
−5.06*
SUSTAIN 626 104 subcutaneous 0.5
1.0
Placebo −0.7*
−1.0*
−2.9*
−4.3*
SUSTAIN 730 40 subcutaneous 0.5
1.0
Delaglutide: 0.75
1.5
−0.4*
−0.41*
−2.26*
−3.55*
Davies et al10 26 Per Os 2.5
5.0
10.0
20.0
40.0
Placebo −0.4*
−0.9*
−1.2*
−1.4*
−1.6*
−0.9
–1.5
–3.6*
−5.0*
−5.7*
Notes: *P<0.01.
Abbreviations: SUSTAIN, semaglutide unabated sustainability in treatment of type 2 diabetes; s.c, subcutaneous; p.os, per os; HbA1c, glycated haemoglobin A1c.
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Similar to other GLP-1 RA, nausea and other gastroin-
testinal (GI)-related symptoms were the most common
complications reported in the SUSTAIN trials.25 Nausea
was reported up to a quarter of patients receiving semaglu-
tide (placebo group 8%). Diarrhea was less frequent; it was
reported to 13% of patients receiving 0.5 mg semaglutide
and 11% of patients receiving 1 mg semaglutide (placebo
group 2%). No case of pancreatitis or pancreatic or medul-
lary cancer was documented, while cases of cholelithiasis
were rare.25 In a large population consisting of 3297
patients (SUSTAIN 6 trial), the incidence of the above GI
disorders was found to be similar. Of note, the rates of
malignant neoplasms were similar in the pooled semaglu-
tide groups (0.5 and 1.0 mg) compared to placebo, although
the highest rate was noted in the semaglutide group receiv-
ing 1.0 mg.31 Microvascular outcomes related to diabetic
retinopathy complications were found to be higher in sema-
glutide group compared to the placebo group, as expected in
the context of rapid HbA1c reductions. These events were
mostly mild or moderate and recorded mainly in patients
with signiﬁcant background diabetic retinopathy.12 This
imbalance in retinopathy outcomes was absent in
SUSTAIN 1–5 trials, yet not infrequently reported follow-
ing abrupt glycaemic improvement (such as in Diabetes
Control and Complications Trial and in newly diagnosed
patients with T2D in the UK Prospective Diabetes Study
(UKPDS 33), or in introduction of insulin in everyday
clinical practice). On the other hand, the incidence of new
or worsening nephropathy was signiﬁcantly decreased in
the semaglutide group compared to placebo.31
Oral semaglutide
Challenges regarding the development of
oral GLP-1 RA
The major barriers preventing the oral administration of a
peptide or protein drug are presented by the enzyme-
mediated peptide degradation and ensuing hydrolysis, the
low permeability of intestinal epithelium and its mucus
layer, and the pH differences between the “acidic” stomach
and the basic intestinal lumen.13,14,32 These challenges
could not be resolved by increasing the administered dose,
since this can lead to a parallel increase in the incidence of
side effects. Consequently, other strategies for oral admin-
istration have been tested and developed, including (but not
limited to) coadministration with enzyme inhibitors, struc-
tural modiﬁcations [cyclization, PEGylation, fatty acid con-
jugates of polypeptides (lipidization), fusing therapeutic
proteins to cobalamin (vitamin B12)], and the use of deliv-
ery carriers or absorption enhancers.32
Novo Nordisk ﬁnally followed the latter approach
(using absorption enhancers) for the development of oral
semaglutide. The selected absorption enhancer was a sys-
tem known as the EligenTM oral drug delivery system,33 a
platform based on the use of synthetic nonacylated amino
acid as carriers, via the natural passive transcellular GI
transport. Speciﬁcally, semaglutide was combined with
sodium N-(8-[2-hydroxybenzoyl] amino) caprylate
(SNAC), which is a small-chain fatty acid that facilitates
semaglutide absorption by acting transcellularly on the
gastric mucosa through a localized pH increase.34,35
Figure 2 visualizes how the Eligen System works in com-
bination with semaglutide.
Considering its novelty, it is no wonder that in vivo
evidence regarding SNAC safety and tolerability is still
scarce. Riley et al36 evaluated the toxicity of SNAC in
rats. In this study, Sprague-Dawley rats received SNAC
alone at 2 g/kg per day orally (for 10–13 weeks), result-
ing in severe toxicity and death. When administrated
orally SNAC at levels of 0.1, 0.5 or 1 g/kg per day to
Wistar rats for 13 weeks, the results indicated that the
maximum dose at which no toxic or adverse event was
recorded (no-observed-adverse-effect level, NOAEL)
was that of 1 g/kg daily.36 Oral SNAC at 1 g/kg per day
was also administered to pregnant Sprague-Dawley rats,
resulting in a minor decrease in maternal body weights,
prolonged gestation and an increase in stillbirths.36 When
0.1 g SNAC was combined with vitamin B12 (cobala-
min), the combination treatment provided a greater mean
absolute bioavailability, compared to B12 alone and was
shown to be well tolerated.37 The half-life of oral sema-
glutide was approximately 1 week, analogous to that of
subcutaneous semaglutide, suggesting that the elimina-
tion phase of semaglutide administered orally is compar-
able with that observed with subcutaneous
administration. Given a similar pattern of systemic expo-
sure between the two routes of semaglutide administra-
tion, it is plausible to expect a similar pattern of efﬁcacy
and safety. Collectively, this evidence suggested that the
use of SNAC as a method of overcoming absorption
barriers should be a safe approach, considering that the
dose under study is several times lower the NOAEL.
However, evidence suggests that minor, reversible epithe-
lial microdamage does occur with the use of SNAC and
whether chronic, repeat exposure and accumulation of
such microdamage may overcome the natural self-healing
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capacity to restore the integrity of the barrier is naturally
still a cause for concern.
Oral semaglutide in speciﬁc
subpopulations
A crucial step in the development was to explore the safety
of the molecule in patients with hepatic or renal impair-
ment. Baekdal et al evaluated the pharmacokinetic effect
of oral semaglutide (once-daily oral semaglutide 5 mg for
5 days followed by 10 mg for 5 days) in 56 patients with
hepatic impairment. Patients were classiﬁed into four
groups according to Child–Pugh criteria (from normal
hepatic function to severe hepatic impairment). No signif-
icant difference in semaglutide plasma concentration
across the four groups was observed and adverse events
were similar across groups.38 In a study by Granhall et al,
patients were categorized into ﬁve groups from normal
renal function to end-stage renal disease on the basis of
estimated creatinine clearance. The patients were
administered the same dosage of oral semaglutide in gra-
dually increasing steps (5 mg for 5 days followed by 10
mg for 5 days). Renal function was shown to have a
neutral effect on the half-life of semaglutide, and similarly,
hemodialysis did not affect the pharmacokinetics of this
drug.39 Thus, oral semaglutide was generally considered to
be safe for use in patients with liver and chronic kidney
disease.
Since the absorption of oral semaglutide is inﬂuenced
by the pH level, it was reasonable to explore whether the
use of commonly prescribed proton pump inhibitors could
change its pharmacokinetics. A single-center, randomized,
open-label study in 54 healthy participants evaluated a
possible interaction between omeprazole on its highest
dosage (40 mg) and oral semaglutide (5 mg for 5 days,
followed by 10 mg for 5 days). Using semaglutide area
under the plasma concentration-time curve over 24 hrs as
the primary outcome, the main ﬁnding was a minor, yet
not statistically signiﬁcant increase in semaglutide
OH
N O
H =
O ONa
+
=    
( lipophilic + flexibility)
SNAC
Semaglutide
Complex
Gastric mucosa
Circulation                   
Figure 2 The Eligen System in the oral semaglutide formulation. Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC) is connected with semaglutide, providing a new
complex with high lipophilic and ﬂexible properties. This complex passes through the mouth to gastric mucosa, acting by increasing the pH and resulting to the semaglutide
deliverance at the circulation.
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exposure when the two drugs were co-prescribed.
However, the small study population, open-label design
and the lack of blindness are signiﬁcant limitations that
need to be considered when interpreting the data.40
Oral semaglutide: safety and efﬁcacy data
from trials
A Phase II, 26-week randomized multicenter, open-label
clinical trial, in which oral semaglutide was compared
with subcutaneous semaglutide and placebo, was designed
and ﬁnally recruited 1106 participants. The design
involved multiple dosing schemes of oral semaglutide,
including once-daily dosages of 2.5 mg, 5 mg, 10 mg, 20
mg or 40 mg. Moreover, two additional 40-mg dosages
were evaluated: the slow escalation extending over 8
weeks (5 mg as ﬁrst dose for 8 weeks and doubling dose
every 8 weeks until 40 mg) and the fast escalation of 2
weeks (5 mg for the ﬁrst 2 weeks and doubling dose every
2 weeks until 40 mg). The most common adverse events
were reported from the GI system. In the standard-dose
escalation of oral semaglutide, GI adverse events were
similar to the subcutaneous semaglutide, yet lower com-
pared to placebo. In the oral semaglutide group, the per-
centage of patients reported GI adverse events were
approximately doubled in the case of fast escalation com-
pared to the standard dose of 2.5 mg and 5 mg. Generally,
the severity of adverse events was higher in the high-dose
oral semaglutide, compared to the subcutaneous or placebo
group. This may explain the higher rates of treatment
discontinuation in these cases. Surprisingly enough, epi-
sodes of hypoglycemia were less common in both the oral
and subcutaneous semaglutide groups compared to the
placebo, a ﬁnding that may constitute an advantage over
other hypoglycaemic agents.41
With regard to its efﬁcacy, oral semaglutide was found
to be of comparable efﬁcacy in reducing HbA1c with the
subcutaneous form, associated with a reduction up to 1.9%
in HbA1c and 6.9 kg in body weight.41 The reduction of
HbA1c and weight from the oral administration of sema-
glutide compared with placebo or other treatments is sum-
marized in Table 2.
A Phase III, 26-week, randomized, double-blinded, pla-
cebo-controlled trial, the PIONEER 1, exploring the oral
form of semaglutide at 3-mg, 7-mg and 14-mg doses in
patients with T2DM is currently ongoing and it is soon
expected to be concluded. Novo Nordisk announced a pre-
liminary analysis from PIONEER 1 trial in February 2018;
the oral semaglutide group achieved a 0.8%, 1.3% and 1.5%
Table 2 Effectiveness of oral semaglutide versus control in glycemic control and weight reduction
Study Duration
(weeks)
Semaglutide Dose (mg) Comparator HbA1c (%)
change
Weight change (kg)
PIONEER 141 26 3
7
14
Placebo −0.7*
−1.2*
−1.4*
−0.2
–1.0*
−2.6*
PIONEER 242 52 14 Semaglutide 25 mg −0.5* −0.9*
PIONEER 343 78 3
4
17
Sitagliptin 100 mg 0.1
–0.3*
−0.7*
−0.8*
−1.6*
−2.4*
PIONEER 444 52 14 Placebo
Liraglutide 1.8 mg
−1.4*
−0.3*
−3.8*
−1.9*
PIONEER 546 25 14 Placebo −1* −2.6*
PIONEER 744 52 On the basis of glycaemic control Sitagliptin 100 mg N/A −2.1*
Davies et al40 26 2.5
5.0
10.0
20.0
40.0
Placebo −0.4*
−0.9*
−1.2*
−1.4*
−1.6*
−0.9
–1.5
–3.6*
−5.0*
−5.7*
Notes: *Denotes statistical signiﬁcance at the level of 0.05.
Abbreviation: HbA1c, glycated haemoglobin.
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reduction in HbA1c and a weight loss of 1.7 kg, 2.5 kg and
4.1 kg at doses 3 mg, 7 mg and 14 mg, respectively. Further
results and secondary end points are expected to be pub-
lished after the completion of PIONEER 1 trial.42
Following this announcement regarding the placebo-
controlled PIONEER 1 trial, the main results from an
active-controlled RCTs (trials in which oral semaglutide is
compared to already approved antidiabetic medications)
were also made public. These active comparators included
SGLT2i empagliﬂozin (PIONEER 2), inhibitors of dipepti-
dyl peptidase 4 (DPP-4 inhibitor) sitagliptin (PIONEER 7)
and GLP1-RA liraglutide (PIONEER 4).
In the 52-week PIONEER 2 trial, the main aim was to
compare oral semaglutide with empagliﬂozin, in 421 patients
inadequately controlled withmetformin. Oral semaglutide was
found to provide a signiﬁcantly greater reduction in HbA1c
and body weight compared to empagliﬂozin at 52 weeks.
Fourteen milligrams of oral semaglutide resulted in a 1.3%
improvement of HbA1c and 4.7 kg weight loss, while empa-
gliﬂozin 25mg achieved a 0.8% decrease inHbA1c and 3.8 kg
weight loss.43 The superiority of oral semaglutide in reducing
HbA1c was observed as early as at week 26. In the PIONEER
3 trial, similar results were reported showing the superiority of
oral semaglutide at 78 weeks (7 mg and 14mg achieved: 0.7%
and 1.1% HbA1c reduction, 2.7 kg and 3.5 kg weight loss)
compared to the 100 mg sitagliptin (0.4% HbA1c reduction,
1.1 kg weight loss) in patients with T2DM inadequately con-
trolled with metformin, with or without sulfonylurea.44
Analyses from PIONEER 4 and 7, both with 52-week dura-
tion, were also announced. In PIONEER 4, 14 mg oral sema-
glutide was compared with 1.8 mg liraglutide (1.2% vs 0.9%
HbA1c reduction, 5 kg vs 3.1 kgweight loss) andwas found to
provide comparable glycemic control and signiﬁcant weight
loss. In the open-label PIONEER 7, ﬂexible once-daily adjus-
table dose of oral semaglutide (3 mg, 7 mg, 14 mg; n=253)
was compared to 100 mg sitagliptin in patients whose type 2
diabetes was uncontrolled with one to two oral glucose-low-
ering medication. Flexible dose adjustment of oral semaglu-
tide led to superior glycemic control and weight loss at week
52 versus sitagliptin and was well tolerated. Adverse events
were more frequent in patients receiving oral semaglutide, yet
generally mild and consistent with the GLP-1 receptor antago-
nist class (nausea). Discontinuation due to adverse events was
more frequent for oral semaglutide (PIONEER 4: 11%,
PIONEER 7: 9%) compared to liraglutide (9%) and sitagliptin
(3%) users.45,46
Oral semaglutide was further investigated against pla-
cebo with regard to its cardiovascular safety (PIONEER 6)
in patients considered to be at high cardiovascular risk,
safety and efﬁcacy in patients with moderate renal impair-
ment (PIONEER 5), and safety and efﬁcacy as an add-on
therapy to insulin-treated patients (PIONEER 8). In
PIONEER 6 trial, 3183 patients with T2DM were rando-
mized to either oral semaglutide or placebo were observed
for cardiovascular events up to a median of approximately
16 months. Major adverse cardiovascular events occurred
in 61 of 1591 patients (3.8%) in the oral semaglutide
group and in 76 of 1592 (4.8%) in the placebo group
(hazard ratio, 0.79; 95% CI, 0.57–1.11; p<0.001 for
noninferiority).47 Despite its relative short duration and
low number of events, the cardiovascular risk proﬁle of
oral semaglutide appears to be (at least) not inferior to that
of placebo. In a 26-week RCT (PIONEER 5), involving
163 patients randomized to oral semaglutide (14 mg once
daily) and 161 patients to the placebo, oral semaglutide
was shown to provide a superior glycemic control (esti-
mated treatment difference of 0.8%) and body weight loss
(estimated treatment difference of −2.5 kg) than placebo
and was found not to affect renal function.48 As an add-on
to insulin with or without metformin (PIONEER 8), oral
semaglutide (at doses of 3, 7 and 14 mg) was shown to be
associated with superior HbA1c and body weight reduc-
tions versus placebo as early as at week 26 and achieved
further reduction in insulin need (except dose 3 mg) at
week 52, without signiﬁcantly increasing the rate of
hypoglycemia.49
The evolution of research starting from the ﬁrst
SUSTAIN trial to the creation of the new oral form of
semaglutide50–55 is depicted in Figure 3.
Areas for future research
The increasing incidence of T2DM, the need to reduce its
burden and the better understanding of its pathogenesis
have led to the discovery of new antidiabetic agents over
the course of the last decade. Suboptimal results regard-
ing the reduction in diabetes-related large-vessel disease
and the recent encouraging cardiovascular disease (CVD)
ﬁndings have refreshed the interest in the properties of
antidiabetic agents, over and beyond the narrow perspec-
tive of HbA1c reduction. This is particularly stressed in
the latest consensus report by the ADA and EASD,56 in
which GLP-1 RAs are generally recommended as the ﬁrst
injectable therapy and the presence of heart disease,
kidney disease and obesity are co-factored in the selec-
tion of antidiabetic agents. In this notion, the family of
GLP1-RAs seems to concentrate on a unique set of
Antza et al Dovepress
submit your manuscript | www.dovepress.com
DovePress
Drug Design, Development and Therapy 2019:132992
SUSTAIN 1
02/2014-08/2014
semaglutide vs placebo
SUSTAIN 2
12/13-08/15
semaglutide vs sitagliptin
SUSTAIN 3
12/13-06/15
semaglutide vs exanetide
SUSTAIN 4
08/14-09/15
semaglutide+insoulin vs glargine
SUSTAIN 5
12/14-11/15
semaglutide+insoulin vs placebo
SUSTAIN 6
02/13-03/16
semaglutide vs placebo
SUSTAIN 7
01\16-06/16
semaglutide vs dilaglutide
Nauck MA et al
published 2016
semaglutide vs placebo
semaglutide vs liraglutide
O’neil PM et al
published 2018
semaglutide vs
placebo
semaglutide vs
liraglutide
Lingvay I et al
published 2018
(with or without
metformin)
semaglutide vs
liraglutide
semaglutide vs placebo
Kaku K et al
published 2018
semaglutide vs
oral antidiabetic drug
Korsatko S et al,
published 2018
(metformin)
semaglutide vs placebo
Effect of oral semaglutide compared with placebo and subcutaneous semaglutide on glycemic control in patients with
type 2 diabetes: a randomized clinical trial. Jama. 2017
Seino Y,
published 2018
semaglutide vs
sitagliptin
Figure 3 The steps from subcutaneous semaglutide to the creation of oral semaglutide.
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favorable characteristics and one major drawback. The
favorable proﬁle refers to their exemplary efﬁcacy in
addressing hyperglycemia, their safety, low risk of hypo-
glycemia, their multilevel pathophysiological superiority,
weight loss and the reported beneﬁts in CVD reduction.
Their major drawback is the subcutaneous route of
administration, constituting barrier to adoption and reason
for treatment discontinuation.
Thus, any agent that would incorporate and maintain
the above set of characteristics while addressing this major
drawback would be a more than desirable addition to the
class of GLP1-RAs, since it would promote medication
adherence, quality of life and thus further consolidating its
beneﬁcial effect in real-life clinical practice. This task is
not straightforward since several issues regarding the ade-
quate protein absorption should be addressed before an
oral GLP1-RA would reach systemic circulation in a safe
and effective dose. Yet, this may be currently a fact with
the introduction of oral semaglutide, a modiﬁed form of
semaglutide with the addition of SNAC carrier.
On the basis of relevant evidence, this novel molecule
seems to maintain the safety and efﬁcacy of the subcuta-
neous form, along with the added beneﬁts of weight loss
and minimization of hypoglycemic episodes. Whether this
molecule has still the impressive CVD effects is demon-
strated with the use of its precursor remains to be explored.
Till date though, its efﬁcacy and safety has already been
showcased in a randomized and parallel group trial, a study
design associated with lower risk of bias and carry-over
effects. The strengths of this trial also refer to its study size,
the constitution of the study population involving patients
from different countries, both of which contribute to the
generalization of the ﬁndings. Moreover, several doses of
oral semaglutide as well as the two types of treatment
escalation were explored and results are provided for each
of them. On the other hand, several shortcomings of the
study should be reported to place the context for interpreta-
tion of its ﬁndings. First, this was an open-label, Phase II
trial (lacks blinding), the duration of the study and follow-
up were short, and thus, no data on hard outcomes, such as
CV disease risk reduction and mortality, were analyzed.41
Overall, oral semaglutide, the single oral GLP1-RA
agent, seems to be an effective and safe hypoglycemic
agent in T2DM and might be considered as a promising
future alternative option and an add-on therapy to further
improve Hb1Ac and reduce weight, while securing a low
risk of hypoglycaemic episodes. More research with Phase
III trials is warranted in order to further consolidate these
ﬁndings across different T2DM subpopulations. Moreover,
studies with a longer follow-up are needed for the evalua-
tion of oral semaglutide with regard to microvascualr or
macrovascular complications of DM, cardiovascular dis-
ease as well as mortality and morbidity. Studies comparing
oral semaglutide with other currently established antidia-
betic agents to evaluate the relative efﬁcacy and cost-
effectiveness are eagerly needed. Finally, the development
of similar molecules, permitting the safe and effective oral
administration of GLP1-RA, would expand the therapeutic
armamentarium of T2DM.
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